Madrid’s health workers strike over hospital privatization

A health worker wearing a black armband which reads, "R.I.P. our job", points at a sign during a protest in MadridBy Paul Day MADRID (Reuters) – Thousands of doctors and nurses went on strike across Spain's Madrid region on Tuesday to protest against plans to spend less public money on health care, the most unpopular part of the government's drive to cut costs. Medical workers plan five one-day strikes every week through to early June over the regional government's plan to tender the management of six public hospitals to private companies. The protest shut down all but urgent care in 34 hospitals and dozens of health centers in the autonomous community of Madrid, a region of 6. …

Kids’ chemical injuries down, but may rise in summer

By Kerry Grens NEW YORK (Reuters Health) – Injuries from gasoline, lamp oil and similar chemicals have dropped considerably among small children in the last decade, according to a new study. “It seems to decline right around 2000, 2001. That’s when the Consumer Products Safety Commission mandated products be placed in child-resistant packaging,” said Dr. Heath Jolliff, the study’s lead author and associate medical director of the Central Ohio Poison Center at Nationwide Children’s Hospital in Columbus. …

Fluids may prevent constipation better than fiber

By Kathryn Doyle NEW YORK (Reuters Health) – Everyone knows that getting enough fiber is a secret to staying “regular,” but a large new study finds that people who got plenty of fluids were the least likely to suffer constipation. The results highlight the importance of hydration, but shouldn’t discount fiber or other lifestyle factors, according to lead author Alayne Markland, of the Department of Veterans Affairs Medical Center in Birmingham, Alabama. “I still think that diet, fiber, exercise and increased fluid should remain the recommendations,” Markland told Reuters Health. …

Baxter’s Alzheimer’s disease drug fails in late-stage trial

By Julie Steenhuysen NEW YORK (Reuters) – In a blow for Alzheimer’s patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients. Baxter’s treatment, known as Gammagard, did show a benefit in some patients with moderate disease and in those who are carriers of a gene known as ApoE4 that raises the risk of Alzheimer’s. The company said it will continue to analyze results in these populations, but more trials would be needed to support the drug’s approval. …

1 64 65 66 67 68 87